Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611564 | 0.97 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL614177 | 0.91 | TSHR (0.61) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL9302745 | 0.89 | SMN1; SMN2 (0.61) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL1995126 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL17530160 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL18099453 | 0.85 | TSHR (0.53) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL612290 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL614626 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL15610112 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL7629096 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
| EP-2763979-B1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-04 | — | — | US | disclosed |
| US-9790359-B2 | Tread rubber composition and pneumatic tire | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20170145031-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-25 | — | — | US | disclosed |
| EP-2857446-A1 | TREAD RUBBER COMPOSITION AND PNEUMATIC TIRE | Sumitomo Rubber Industries, Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8871766-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8865717-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8835564-B2 | Method for producing modified conjugated diene-based polymer, and method for producing polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140088256-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, AND METHOD FOR PRODUCING POLYMER COMPOSITION | ZEON CORPORATION (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-8299179-B2 | Conjugated diene-based polymer, conjugated diene-based polymer composition, and process for producing conjugated diene-based polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120041136-A1 | CONJUGATED DIENE-BASED POLYMER, CONJUGATED DIENE-BASED POLYMER COMPOSITION, AND PROCESS FOR PRODUCING CONJUGATED DIENE-BASED POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-20170145031-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | SMN1; SMN2 6/4885TSHR 4345/4885ALDH1A1 59/4885 |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | SMN1; SMN2 11/4885TSHR 3992/4885ALDH1A1 300/4885 |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | SMN1; SMN2 11/4885TSHR 3992/4885ALDH1A1 300/4885 |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | SMN1; SMN2 6/4885TSHR 4289/4885ALDH1A1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.